3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
3
Glioma
2
Diffuse Intrinsic Pontine Glioma
2
Astrocytoma
2
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Optic Nerve Glioma
1
Oligodendroglioma
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Neoplasm Metastasis
1
Medulloblastoma
1
Liver Cirrhosis
1
Gliosarcoma
1
Gastrointestinal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Brain Stem Neoplasms
1
Brain Neoplasms
1
Interventions
Temozolomide
162
Radiosurgery
114
Radiotherapy
99
Bevacizumab
95
Magnetic Resonance Spectroscopy
64
Carboplatin
48
Etoposide
34
Surgical Procedures, Operative
33
Irinotecan
33
pembrolizumab
32
Nivolumab
32
Cyclophosphamide
32
Erlotinib Hydrochloride
31
Radiation
29
Carmustine
28
Cisplatin
25
Lomustine
24
Trastuzumab
23
Ipilimumab
23
Filgrastim
23
Vincristine
20
Mental Status and Dementia Tests
20
Aminolevulinic Acid
19
Topotecan
18
Pemetrexed
18
Capecitabine
18
Specimen Handling
17
Sorafenib
15
Radiotherapy, Intensity-Modulated
15
Imatinib Mesylate
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Brain Neoplasms
×
Mebendazole
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn